At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 58 enrolled
Drug / intervention
KU-0059436 (AZD2281)(PARP inhibitor) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating KU-0059436 (AZD2281)(PARP inhibitor) for Ovarian Neoplasm. Completed, enrolled 58 participants across 11 sites in 5 countries.
Detailed Summary
The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Neoplasm
CountriesAustralia, Germany, Spain, Sweden, United States
CollaboratorsKuDOS Pharmaceuticals Limited
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedJun 2007
Primary CompletionMar 2009
Study CompletionJul 2017
TodayJul 2026
First PostedJun 29, 2007
Enrollment StartJun 11, 2007
Primary CompletionMar 17, 2009
Study CompletionJul 20, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.0 years ago
Interventions
KU-0059436 (AZD2281)(PARP inhibitor)drug
oral
KU-0059436 (AZD2281)(PARP inhibitor)drug
oral